Introduction
Autoimmune hemolytic anemia (AHA) is the oldest recognized autoimmune disease in humans. It is characterized by the destruction of red blood cells (RBC) due to production of Coombs' anti-erythrocyte autoantibodies.
Since the discovery of the spontaneous development of AHA in the New Zealand black (NZB) strain of mice, 1 this model has been widely used in studies aiming to define the immunological mechanisms underlying this disease.
Although the molecular nature of RBC autoantigens responsible for the induction of this autoimmune response has not been well characterized, it is clear that anti-RBC Coombs' antibodies specific for exposed surface determinants of intact RBC are of primary importance in the development of AHA. 2 Studies of anti-mouse RBC monoclonal autoantibodies derived from NZB mice revealed that IgG Fc receptor-and complement receptor-dependent erythrophagocytosis by Kupffer cells, but not complement-mediated hemolysis, is the major pathogenic mechanism for the development of AHA. [3] [4] [5] Furthermore, it has been suggested that CD5 + B1 cells in NZB mice may be involved in AHA because of a marked expansion of this subset in NZB mice 6 and because of the production of Coombs' antibodies by B1 cells in 4C8 anti-RBC transgenic mice. 7, 8 Although B1 cells are known to produce several types of natural autoantibodies, 9, 10 it is still unclear whether these cells are indeed responsible for the spontaneous production of pathogenic Coombs' antibodies in NZB mice.
The pathogenesis of AHA is a complex process in which many factors apparently play essential roles. Among these, the importance of genetic factors in determining the incidence, onset and severity of AHA has become clear.
Notably, NZB mice have proved to be a powerful tool to define the genetic mechanism of the disease. Previous studies have provided evidence that AHA is under some form of polygenic control, with several genetic factors contributing to the overall susceptibility and progression of the disease. [11] [12] [13] [14] [15] For personal use only. on October 28, 2017 . by guest www.bloodjournal.org From Early genetic analyses involving the NZB and NZC strains suggested the presence of two dominant or co-dominant AHA-susceptibility genes, Aia1 (autoimmune anemia 1) and Aia2. 14 antibody production was negatively regulated by two dominant modifying genes present on C57BL/6 (B6) chromosomes 7 and 10. 16 In contrast, the precise chromosomal location of NZB-derived susceptibility loci has never been defined.
The BXSB Y chromosome-linked mutant gene Yaa (Y-linked autoimmune acceleration) promotes the accelerated development of systemic lupus erythematosus (SLE) in BXSB mice and in their F1 hybrids with autoimmuneprone NZB, NZW and MRL mice. 17 Yaa is able to accelerates the spontaneous production of various autoantibodies, including Coombs' antibodies, through interaction with autoimmune susceptibility genes present in different lupusprone mice, which by themselves are not sufficient to trigger lupus-like autoimmune responses. 18, 19 In contrast, the effect of the Yaa mutation is minimal in mice which are not predisposed to autoimmune diseases. Thus, genetic analyses involving Yaa represents a useful approach for unraveling the susceptibility loci implicated in murine AHA.
In the present study, we first determined whether (NZB x B6.Yaa)F1 male mice were able to develop Coombs' antibodies in the presence of the Yaa mutation. Then, we used B6 x (NZB x B6.Yaa)F1 BC male mice and congenic mice bearing mapped susceptibility intervals to identify critical NZB-derived AHA-susceptibility loci. Here we report the mapping of two major quantitative trait locus (QTL) contributing to Coombs' antibody production on NZB 3) , and on NZB chromosome 1 corresponding to the Nba2 (NZB autoimmunity 2) locus, which is known to control the overall production of lupus autoantibodies. 20, 21 The contribution of these two loci to AHA was confirmed by the analysis of congenic B6 mice bearing either of the NZB-derived susceptibility intervals.
Furthermore, our results showed a lack of association of Coomb's antibody production with expansion of B1 cells in the development of AHA.
Materials and methods

Mice
NZB mice (H2 d ) were purchased from the Jackson Laboratory (Bar Harbor, ME). B6 mice (H2 b ) bearing the Yaa mutation (B6.Yaa) were established by repeated backcrossing (n > 20), as described previously. 19 (NZB x B6.Yaa)F1 and B6 x (NZB x B6.Yaa)F1 BC mice were obtained by local breeding in our animal facility. B6.NZB-Nba2 (B6.Nba2) congenic mice were generated as described previously. 20 B6 mice bearing the NZB-Aia3 locus (B6.Aia3) on chromosome 7
were generated by backcrossing a ~23 centiMorgans (cM) NZB-derived interval encompassing markers D7Mit154 and D7Mit194 onto the B6 background using marker-assisted selection, as described previously. 22 After six generation of backcrossing, siblings were intercrossed to generate congenic mice homozygous for the NZB chromosome 7 intervals. Males of all congenic mice used in the present study carry the Yaa mutation. Blood samples were collected by orbital sinus puncture.
Detection of Coombs' antibodies
A flow cytometric assay was used to detect Coombs' antibodies using biotinylated rat anti-mouse k chain mAb (H139.52.1.5), followed by PEconjugated streptavidin, as described previously. 23 The results are expressed as mean fluorescence intensity (MFI), analyzed with a FACSCalibur (BD
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Biosciences, San Jose, CA). Analysis of circulating RBC from 4 month-old B6 male mice in multiple tests (10 mice in each assay) yielded consistent values of MFI, which were in the range of 4.0 to 4.5, and means + 3SD never exceeded more than 9.0. Therefore, a positive Coombs' test was defined as >9.0.
Determination of hematocrits (Ht)
Blood samples were collected into heparinized microhematocrit tubes and centrifuged in a microfuge, as described previously. 3 The percentage of packed RBC volume was directly measured after centrifugation. Mean Ht values (± SD) of 4 month-old B6 male mice (n = 30) was 44.9 ± 1.7. Abnormal Ht values were defined as lower than 39.8% (mean Q 3SD).
Genotyping and statistical analysis
Genotypes were determined by PCR using 95 selected microsatellite markers either purchased from Research Genetics (Huntsville, AL) or Invitrogen (Carlsbad, CA). DNA from NZB, B6, (NZB x B6)F1 and BC mice were extracted from tail samples kept at -70 °C before use. PCR amplification was conducted with RED Taq DNA polymerase (Sigma-Aldrich, Saint Louis, MO) using a GeneAmp PCR system 9700 thermal cycler (Applied Biosystems, Foster City, CA), as described. 22 The positions of the microsatellite markers with respect to the centromere were obtained from the Mouse Genome 
Flow cytometric analysis
Flow cytometry was performed for the enumeration of B1 cells in peritoneal cavity using a FACSCalibur. The following antibodies were used:
anti-B220 (RA3-6B2), anti-CD5 (53-7.3) and anti-CD11b (M1/70) mAb. Staining was performed in the presence of saturating concentration of 2.4G2 antiFc RII/III mAb, as described previously. 26 
Results
Development of Coombs' antibodies in autoimmune-prone (NZB x B6.Yaa)F1
Yaa male mice, but not in B6.Yaa male mice
We assessed the possible spontaneous production of Coombs' antibodies and the development of anemia in (NZB x B6.Yaa)F1 male mice, which develop severe SLE, with a 50% mortality rate at 14 months of age. 21 To further examine the effect of Aia3 and Nba2 on Coombs' antibody production, Coombs' antibody activities were plotted based on the genotype at the Cd22 and Fcgr2 loci, corresponding to Aia3 and Nba2, respectively, in BC mice. Among different groups of mice, classified according to the combination of genotypes, mice heterozygous for both loci (i.e. bearing the NZB allele) had the highest Coombs' antibody levels (MFI ± SD: 32.8 ± 40.2), which significantly differed from those in mice heterozygous at only Cd22 (14.3 ± 15.2, p < 0.01) or Fcgr2 (9.7 ± 8.1, p < 0.005), and in mice homozygous for the B6 alleles at both loci (7.3 ± 10.7, p < 0.001) (Figure 4 ). These data suggested an additive effect of both Aia3 and Nba2 to the production of Coombs' antibodies. Notably, levels of Coombs' antibodies in mice heterozygous at Cd22 only were significantly higher than those of mice homozygous for the B6 alleles at both loci (p < 0.005), which was not the case for mice heterozygous at Fcgr2 only, consistent with the stronger linkage of Coombs' antibody production with the Aia3 locus than with the Nba2 locus.
Development of Coombs' antibodies in B6 congenic mice bearing the NZB-
Aia3 locus
To confirm the contribution of the Aia3 locus to the development of AHA, B6.Aia3 congenic mice homozygous for an NZB-derived interval flanked by markers D7Mit154 and D7Mit194 (~23 cM interval) were produced, and analyzed for the spontaneous production of Coombs' antibodies. As expected from the results obtained from BC mice, the majority (14 of 18) of B6.Aia3 male mice bearing the Yaa mutation spontaneously developed increased Coombs' antibody activities at 10 months of age ( Figure 5 and Table 1 ). However, their titers were significantly lower than those observed with (NZB x B6.Yaa)F1 Yaa male mice (p < 0.0005). Although the incidence of positive Coombs' antibody tests was less than that of their Yaa male counterparts (p < 0.005), 39% of B6.Aia3 females exhibited significant Coombs' antibody activities, as compared with 10 month-old B6.Yaa male and female mice (p < 0.01 and p < 0.0005, respectively).
Ht values were also decreased in 61% of B6.Aia3 Yaa male mice, while only one of 18 female congenic mice displayed a significantly decreased Ht value at 10 months of age (p < 0.0001, Figure 5 and Table 1 ). Notably, none of 10 month-old B6.Yaa male and female mice displayed abnormally reduced Ht values.
A unique cellular abnormality in NZB mice is the expansion of CD5 + B1 cells in the peritoneal cavity. 6 In addition, studies in 4C8 Coombs' anti-RBC transgenic mice have demonstrated that B1 cells present in this compartment can produce pathogenic Coombs' antibodies. 7, 8 Therefore, we determined whether the selective association of the Aia3 locus with Coombs' antibody production was related to the expansion of the B1 subset. The analysis of peritoneal cavity cells from 2 and 8 month-old B6.Aia3 Yaa male mice showed no increases in percentages of CD5 + B1a and CD5 Q B1b subsets, as compared with B6.Yaa male mice ( Figure 6 ). Notably, as reported previously, 6 the B1 subset was greatly expanded in 2 month-old NZB mice.
Development of Coombs' antibodies in B6 congenic mice bearing the NZB-
Nba2 locus
We have recently shown that B6.Yaa male mice bearing the NZB-Nba2 locus spontaneously produce increased levels of IgG anti-nuclear autoantibodies and gp70 IC, and develop severe glomerulonephritis. 21 
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Coombs' antibody production in B6 mice was also linked to Nba2, we assessed the spontaneous production of Coombs' antibodies in B6 mice bearing an Nba2 interval flanked by markers D1Mit47 and D1Mit461 (~23 cM interval). The presence of Coombs' antibodies was indeed detectable in B6.Nba2 Yaa male mice at 10 months of age ( Figure 5 and Table 1 ). Although their incidence (40%) was much lower than that of B6.Aia3 Yaa males (p < 0.01), it was significantly elevated as compared with B6.Yaa male mice (p < 0.005). Moreover, 20% of them had abnormally low Ht values ( Figure 5 and Table 1 with Nba2 on chromosome 1, promotes the development of AHA, likely as a result of its effect on overall production of lupus autoantibodies. 20, 21 Earlier genetic studies using a few selected markers claimed that Aia1 is a dominant NZB AHA-susceptibility allele, and these studies suggested that it is located on NZB chromosome 4. 14 However, the existence of this locus was not confirmed in the present study as well as in a previous genome-wide linkage analysis of (B6 x NZB)F1 x NZB BC mice. 16 If Aia1 is indeed of a dominant nature, this would explain why this locus was not revealed by the analysis of (B6 x NZB)F1 x NZB BC mice. However, the presence of such a locus should be It should be stressed that the proximal region of NZB chromosome 7
contains not only Aia3 but also the recently identified Nba5 locus, which selectively regulates the production of nephritogenic gp70 IC. 21 However, the Nba5 locus, peaking at the D7Nds5 marker, was located more than 10 cM distal to Aia3, peaking at the locus Cd22. Since current B6.Aia3 congenic mice carry an NZB-derived interval including both Aia3 and Nba5, we cannot formally prove that these two loci are distinct and differentially regulate anti-RBC and antigp70 autoantibody responses. However, this region is unable to promote the development of anti-DNA and anti-chromatin autoantibody production. 21 Thus, the candidate genes for Aia3 and Nba5 are most likely to be different from those promoting general hyperresponsiveness of B and/or T cells, thereby enhancing overall autoimmune responses in NZB mice. It should also be stressed that the Aia3 locus is distinct from a B6 modifying locus for Coombs' antibody production, reported by recent studies in (B6 x NZB)F1 x NZB BC mice, 16 because the latter was mapped on mid chromosome 7, peaking at the
D7Mit30 marker (~20 cM distal to Aia3).
For
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The selective effect of Aia3 on Coombs' antibody responses is intriguing, especially when compared to the effect of Nba2 and the B6 chromosome 17 loci on overall autoantibody production. The LOD score curve revealing the Aia3 locus peaked in the vicinity of the Cd22 gene, which encodes a B cell-restricted adhesion molecule that binds 2,6-linked sialic acid, and functions as a negative regulator of B-cell receptor (BCR) signaling. 28 Significantly, NZB mice carry a defective Cd22 a allele, and CD22 expression on Cd22 a B cells is lower at steady state and less up-regulated following B cell activation than that of B cells from B6 mice bearing the Cd22 b allele. 29 In addition, Cd22 a B cells appear to express aberrant forms of CD22, which differ in the N-terminal sequences constituting the ligand-binding site, due to the synthesis of abnormally processed Cd22 mRNA. 29 Indeed, we have recently observed that CD22 molecules expressed on
Cd22 a B cells are less efficient in the binding to CD22 ligand (CD22L) than their
Cd22 b counterparts (submitted for publication). It has been proposed that simultaneous engagement of BCR by autoantigen and of CD22 by CD22L could be a mechanism to prevent the activation of autoreactive B cells specific against membrane antigens on self target cells, if the latter co-expresses CD22L. 30 Notably, CD22L is abundantly expressed on RBC. 31 In addition to the Aia3 locus, the present study has shown that B6.Yaa males bearing the Nba2 locus were able to develop Coombs' antibodies.
However, in contrast to the selective effect of Aia3, this production of Coombs' antibodies is likely to be a result of the general autoimmune potentiating effect of Nba2, which is also able to promote the formation of anti-nuclear autoantibodies and gp70 IC. 20, 21 The Fcgr2 allele of the NZB strain has been suggested as one possible candidate gene located within the Nba2 interval. The 20 in agreement with the demonstration of a critical role of type I interferon in the pathogenesis of AHA in NZB mice. 34 More recently, lupus susceptibility has been shown to be associated with polymorphism of the SLAM/CD2 gene family (Cd244, Cd229, Cs1, Cd48, Cd150, Ly108 and Cd84). 35 Since these genes encode cell surface molecules that play a role in the modulation of activation and signaling of immune cells, they are also good candidates for predisposition to lupus-like autoimmune disease. Analysis of Nba2 subcongenic mice will help define the respective contributions of the Fcgr2, Ifi202 and SLAM/CD2 genes to Nba2-linked autoimmune traits.
It has long been claimed that CD5 + B1 cells could be the major subset involved in the production of Coombs' antibodies in NZB mice. This is based on the findings that NZB mice display an expansion of B1 cells, 6 and that the depletion of B1 cells via intraperitoneal injection of distilled water delayed the onset of AHA in NZB mice. 36 Furthermore, it has been shown that the 4C8 anti-RBC transgenic B cells are enriched in the B1 population of the peritoneal cavity, and secrete 4C8 Coombs' antibodies. 7, 37, 38 However, our present and previous analysis of B6.Aia3 and B6.Nba2 mice failed to show any significant expansion of B1 cells. 39 These results indicate that the NZB-determined B1 cell expansion is not required for the production of Coombs' antibodies in NZB mice and is probably due to a genetic contribution distinct from Nba2 and Aia3.
Our present BC study also revealed an AHA-susceptibility locus of B6 origin on chromosome 17. This locus overlapped with the H2 complex and promoted various lupus autoimmune responses. 21 The production of various 
